Boehringer Ingelheim

This study looks at how well the drug Jardiance works for people with a certain type of heart failure (HFrEF) compared to usual treatments. About 5,000 adults in China will be followed to see if Jardiance reduces the risk of death from heart problems or hospital stays for heart f…

This study tests nerandomilast, a medicine already approved for adults with lung scarring, in children aged 2 to 17 with fibrosing interstitial lung disease. About 35 children will take the drug or a placebo for 6 months, then all receive the drug for at least 2 years. Researcher…

This early-stage study will give verducatib pills daily for 4 weeks to 12 healthy Chinese adults. The goal is to measure how the drug moves through the body and check for side effects. Participants must be healthy and not expect any direct medical benefit.

This study looks at how a medicine called BI 3000202 is handled by the body in people with and without liver problems. About 44 adults aged 18 to 80 will take one tablet of the medicine. Researchers will measure the drug levels in the blood and check for side effects over about o…

This early-stage study tests a new drug called BI 3821001 in healthy men aged 18 to 55. The main goal is to see if it is safe and how the body processes it. Participants receive either a single dose of the drug or a placebo. No direct health benefit is expected, but the results w…

This study will observe about 3,000 adults in China with heart failure with preserved ejection fraction (HFpEF) who are starting the drug Jardiance. Researchers will track how often patients are hospitalized for heart failure or die from heart-related causes. The goal is to see h…